Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)

NCT06260709 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT06260709
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06260709 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Extension Study of Long-term Safety and Efficacy of NNC6019-0001 in Participants With Transthyretin Amyloid Cardiomyopathy (ATTR CM)
Lead sponsor
Novo Nordisk A/S
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 20, 2024
Completion date
February 9, 2030
Enrollment
88 (estimated)
Sites
38

Conditions

As the registry lists them; a condition with its own page is linked.

transthyretin amyloid cardiomyopathy (attr cm)